https://www.selleckchem.com/products/tng908.html
Objectives Complete responses have been observed in NPM1-mutated AML patients with dactinomycin, a nucleolar stress-inducing drug. Here, we report a single-center experience of compassionate use of dactinomycin in untreated or relapsed/ refractory NPM1-mutated AML. Methods From September 2015 to February 2019, 26 adult patients with NPM1-mutated AML received dactinomycin in different situations front-line treatment in 4 unfit patients (16%); morphologic (n = 16, 62%), molecular relapses (n = 4, 16%), refractory disease (n = 1, 13%), or p
Like
Comment
Share
